CTMX Q2 2019 Earnings — CytomX Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CTMXCytomX Therapeutics, Inc.

$822M

Q2 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$9M-57.8% YoY

Gross Profit

$9M100.0% margin

Operating Income

-$31M-346.5% margin

Net Income

-$29M-321.3% margin

EPS (Diluted)

$-0.64

QoQ Revenue Growth

-69.4%

Cash Flow

Operating Cash Flow

-$49M

Free Cash Flow

-$49M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$405M

Total Liabilities

$304M

Stockholders' Equity

$102M

Cash & Equivalents

$149M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$9M	$21M	-57.8%
Gross Profit	$9M	$21M	-57.8%
Operating Income	-$31M	-$13M	-135.6%
Net Income	-$29M	-$13M	-115.4%